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Abstract The effect of deferasirox dosing tailored for iron
burden and iron loading based on liver iron concentration
(LIC) was assessed over 1 year in less versus more heavily
iron-overloaded patients in a substudy of the Evaluation of
Patients’ Iron Chelation with Exjade®. Deferasirox starting
dose was 10–30 mg/kg/day, depending on blood transfusion
frequency, with recommended dose adjustments every
3 months. Therapeutic goals were LIC maintenance or reduc-
tion in patients with baseline LIC <7 or ≥7 mg Fe/g dry
weight (dw), respectively. Changes in LIC (R2-magnetic
resonance imaging) and serum ferritin after 1 year were
assessed. Adverse events (AEs) and laboratory parameters
were monitored throughout. Of 374 patients, 71 and 303 had
baseline LIC <7 and ≥7 mg Fe/g dw, respectively; mean
deferasirox doses were 20.7 and 27.1 mg/kg/day (overall
average time to dose increase, 24 weeks). At 1 year, mean
LIC and median serum ferritin levels were maintained in the
low-iron cohort (−0.02±2.4 mg Fe/g dw, −57 ng/mL; P0not
significant) and significantly decreased in the high-iron cohort
(−6.1±9.1 mg Fe/g dw, −830 ng/mL; P<0.0001). Drug-
related gastrointestinal AEs, mostly mild to moderate, were
more frequently reported in the <7 versus ≥7 mg Fe/g dw
cohort (39.4 versus 20.8%;P00.001) and were not confound-
ed by diagnosis, dosing, ethnicity, or hepatitis B and/or C
history. Reported serum creatinine increases did not increase
in low- versus high-iron cohort patients. Deferasirox doses of
20 mg/kg/day maintained LIC <7 mg Fe/g dw and doses of
30 mg/kg/day were required for net iron reduction in
the high-iron cohort, with clinically manageable safety
profiles. The higher incidence of gastrointestinal AEs at
lower iron burdens requires further investigation.
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Introduction
Patients with conditions resulting in iron overload, where
their liver iron concentration (LIC) exceeds 7 mg Fe/g dry
weight (dw), are at an increased risk of progressive organ
dysfunction and/or early death due to iron-related compli-
cations [1–8]. Transfusion therapy in the treatment of
patients with blood disorders such as β-thalassemia major,
sickle cell disease (SCD), and myelodysplastic syndromes
(MDS) rapidly leads to iron overload and subsequent
tissue and organ damage unless effective chelation therapy is
used to control tissue iron levels [9, 10]. Key goals in the
management of iron overload are, therefore, to decrease LIC
below 7mg Fe/g dw and tomaintain LIC below this level over
the long term.
Although many studies have shown the efficacy and
safety of the oral iron chelator deferasirox in the treatment
of iron overload [11–14], there are limited efficacy and
safety data in patients with LIC <7 mg Fe/g dw receiving
doses of deferasirox at the recommended starting dose of
20 mg/kg/day [15, 16]. The international, multicenter
Evaluation of Patients’ Iron Chelation with Exjade®
(EPIC) study was the first to prospectively demonstrate
that effective chelation can be achieved using fixed
starting doses of deferasirox based on ongoing iron
intake from blood transfusions, with subsequent dose
titration guided by serum ferritin levels and safety
markers [11]. Although deferasirox efficacy in EPIC
was primarily monitored using serum ferritin, a large
subset of patients was assessed by noninvasive LIC
measurement using R2-magnetic resonance imaging
(R2-MRI). In this subset of patients, the efficacy and
safety of deferasirox in patients with lower and higher
iron burdens were, therefore, assessed. This predefined
analysis evaluates deferasirox for maintaining LIC in
patients with baseline LIC <7 mg Fe/g dw and for
reducing LIC in those with baseline LIC ≥7 mg Fe/g dw.
Methods
The EPIC study was an international, multicenter, prospec-
tive, 1-year, open-label, phase IIIb study, for which the study
design, inclusion/exclusion criteria, and dosing information
have been described in full previously [11]. This paper reports
the findings of a predefined liver MRI substudy of EPIC.
Patients who underwent LIC assessments were recruited
from the 25 centers with the appropriate apparatus and
expertise to perform liver R2-MRI assessment. Eligible
patients signed an additional informed consent form to
participate in the MRI substudy. All study procedures
were conducted in accordance with Good Clinical Practice
guidelines and the Declaration of Helsinki.
R2-MRI methodology
The magnetic resonance imagers used in the study were
located at the investigators’ centers and were of a specification
stipulated by Inner Vision Biometrics Pty Ltd (Claremont,
WA, Australia), which conducted central analysis of the
acquired data. The assessment of the R2-MRI data was
conducted on-site by suitably qualified personnel. MRI
systems had 1.5-T static field strengths and were capable of
acquiring single spin-echo images with minimum spin-echo
times of at most 6 ms. Surface chest/torso coils were used for
radio frequency signal detection. MRI data analysis followed
the method of St Pierre et al. [17]. Briefly, R2 values were
calculated throughout a liver slice by curve fitting the
equation for the biexponential decay in transverse mag-
netization following a single spin-echo pulse sequence
to the voxel intensity data as a function of echo time.
A mean R2 value was calculated for each voxel by
summation of the fast and slow components of the
proton transverse relaxation rate weighted by their relative
population densities [17].
Assessments
Efficacy was assessed based on changes from baseline in
LIC and serum ferritin levels after 1 year of treatment
with deferasirox. Patients with a baseline LIC of ≥7 mg
Fe/g dw had a therapeutic goal of LIC reduction, while
for patients with a baseline LIC of <7 mg Fe/g dw, the
therapeutic goal was maintenance. LIC was determined at
baseline, 6 months, and 12 months. Serum ferritin levels
were assessed at baseline and every 4 weeks. Safety and
tolerability were evaluated throughout the study by monitoring
the incidence and type of adverse events (AEs) and by
assessing routine laboratory parameters.
Statistical methods
The full analysis set (FAS) population comprised all
patients who successfully passed screening and were
selected for participation in the R2-MRI substudy. All
efficacy results are presented from the FAS population
unless specified. The per protocol (PP) population comprised
all patients who received the study drug and whose LIC
was determined by R2-MRI at baseline and after
12 months. The safety population comprised all patients
who received at least one dose of study medication and
had at least one post-baseline safety assessment. Analy-
sis sets were further divided by baseline LIC <7 and
≥7 mg Fe/g dw for the assessment of efficacy and
safety. Efficacy (LIC and serum ferritin) was also
assessed based on average actual deferasirox dose
(<15, 15 to <25, 25 to <35, and ≥35 mg/kg/day).
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Descriptive statistics were provided for LIC at baseline,
6 months, and 12 months and for the absolute change in LIC
(6 months minus baseline and 12 months minus baseline).
Descriptive statistics were provided for serum ferritin levels
at baseline and every 4 weeks and for the absolute
change in serum ferritin levels at 12 months (12 months
minus baseline). For LIC change from baseline, reported
P values are based on one-sided paired t tests (null hypothesis:
absolute change<3). P values for serum ferritin or LIC by
additional subgroups are based on two-sided paired t tests
(null hypothesis: absolute change00). Safety and demo-
graphic data were assessed using summary statistics.
Reported P values for safety parameters are based on a chi-
squared test. Logistic regression analyses were conducted
to investigate the impact of baseline patient characteristics
on the occurrence of gastrointestinal AEs in patients with
baseline LIC <7 and ≥7 mg Fe/g dw. Potential con-
founding factors such as diagnosis, dosing, ethnicity,




A total of 374 patients were included in the substudy; 71
and 303 with baseline LIC <7 and ≥7 mg Fe/g dw,
respectively. Baseline characteristics were generally compara-
ble for patients with baseline LIC <7 and ≥7 mg Fe/g dw.
However, the proportion of Oriental patients was lower
in the <7 mg Fe/g dw cohort compared with the ≥7 mg
Fe/g dw cohort (21.1 versus 48.8 %), and the proportion
of patients with a history of hepatitis B and/or C was
higher in the <7 mg Fe/g dw cohort than in the ≥7 mg
Fe/g dw cohort (40.8 versus 21.8 %; Table 1). The
majority of patients had thalassemia (81.7 and 85.5 %
for the <7 and ≥7 mg Fe/g dw cohorts, respectively) and
had received prior chelation therapy (84.5 and 92.4 %),
most commonly with deferoxamine (DFO) monotherapy
(70.4 and 63.0 %). Mean baseline LIC was 4.6 mg Fe/g dw in
the baseline LIC <7 mg Fe/g dw cohort and 25.0 mg Fe/g dw
in the ≥7 mg Fe/g dw cohort; median baseline serum ferritin
levels were 1,479 and 4,139 ng/mL, respectively.
Deferasirox dosing and iron intake
In the <7 mg Fe/g dw cohort, the majority of patients
started on deferasirox 20 mg/kg/day (n067, 94.4 %);
three patients received 10 mg/kg/day and one patient
received 30 mg/kg/day. In the ≥7 mg Fe/g dw cohort,
171 patients (56.4 %) started on deferasirox 20 mg/kg/day
and 123 (40.6 %) started on 30 mg/kg/day, 4 patients
started on 10 mg/kg/day, 1 patient started on 15 mg/kg/day,
and 2 patients each started on 25 or 35 mg/kg/day. Mean
actual deferasirox dose in the <7 and ≥7 mg Fe/g dw cohorts
was 20.7±5.4 and 27.1±7.1 mg/kg/day, respectively. In
patients with thalassemia, the dose was 21.3±5.3 and
28.3±6.6 mg/kg/day in the <7 and ≥7 mg Fe/g dw
cohorts, respectively.
Overall, 29 patients (40.8 %) with baseline LIC
<7 mg Fe/g dw and 149 patients (49.2 %) with baseline
LIC ≥7 mg Fe/g dw received dose increases during the
study. The level to which doses were increased was lower in
the <7 mg Fe/g dw cohort than in the ≥7 mg Fe/g dw cohort:
There were only five occasions when dose was increased
to >30 mg/kg/day in the <7 mg Fe/g dw cohort at any
point during the study, compared with 124 occasions in
the ≥7 mg Fe/g dw cohort (Fig. 1). In addition, the median
time to dose increase was greater in the <7 mg Fe/g dw cohort
than in the ≥7 mg Fe/g dw cohort (Fig. 1). Mean iron
intake during the study was comparable in the <7 mg Fe/g dw
cohort (0.38±0.31 mg/kg/day) and ≥7 mg Fe/g dw cohort
(0.34±0.18 mg/kg/day).
Efficacy of deferasirox in patients with LIC
<7 and ≥7 mg Fe/g dw
Mean LIC was maintained over 12 months in the LIC
<7 mg Fe/g dw cohort (absolute change, −0.02±2.4mg Fe/g dw;
P0not significant), whereas in the ≥7 mg Fe/g dw cohort,
mean LIC decreased significantly from 25.0±10.6 mg Fe/g dw
at baseline to 18.9±12.0 mg Fe/g dw at 12 months
(absolute change, −6.1±9.1 mg Fe/g dw; P<0.0001;
Fig. 2). These findings were supported by results for
the PP population (n0332): In the LIC <7 mg Fe/g dw cohort,
LIC was maintained over 12 months (4.6±1.6 mg Fe/g dw
at baseline and 4.7±2.7 mg Fe/g dw after 12 months); in
the ≥7 mg Fe/g dw cohort, mean LIC decreased from
25.0±10.6 mg Fe/g dw at baseline to 19.1±12.1 mg Fe/g dw
after 12 months (absolute change, −6.1±9.0 mg Fe/g dw).
A summary of the number of patients with LIC <7, 7 to <10,
and ≥10 mg Fe/g dw at baseline and after 12 months, by
baseline LIC category, is shown in Table 2.
Median serum ferritin levels were maintained at
approximately baseline levels in the <7 mg Fe/g dw
cohort (absolute median change, −57 ng/mL; P0not
significant) and decreased significantly from 4,139 ng/mL
at baseline to 3,176 ng/mL at 12 months in the ≥7 mg Fe/g dw
cohort (absolute median change, −830 ng/mL; P<0.0001;
Fig. 3). The number of patients in the <7 mg Fe/g dw
cohort who achieved serum ferritin levels <1,000 ng/mL
by the end of the study (n016) was similar to the
number at baseline (n017). In the ≥7 mg Fe/g dw cohort,
the number of patients with serum ferritin levels <1,000 ng/mL
increased from 3 at baseline to 16 at end of the study.
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LIC and serum ferritin levels were maintained in the
<7 mg Fe/g dw cohort, regardless of average actual
deferasirox dose (Table 3). In the ≥7 mg Fe/g dw cohort,
reductions in LIC and serum ferritin levels appeared to
be dose-related (Table 3). Indeed, in contrast to the
overall ≥7 mg Fe/g dw cohort, there was no significant
change in serum ferritin levels in patients whose average
actual deferasirox dose was <15 mg/kg/day (Table 3).
Discontinuations and safety
Overall, 63 out of 71 (88.7 %) and 274 out of 303 (90.4 %)
patients in the <7 and ≥7 mg Fe/g dw cohorts completed the
study, respectively; 54 and 241 of these were patients
with thalassemia. Reasons for discontinuation in the <7
and ≥7 mg Fe/g dw cohorts were, respectively, AEs (n06,
8.5 % and n011, 3.6 %), consent withdrawal (0 % and n04,
1.3%), unsatisfactory therapeutic effect (n01, 1.4% and n01,
0.3 %), abnormal laboratory value (n01, 1.4 % and n01,
0.3 %), protocol violation (0 % and n04, 1.3 %), no longer
required study drug (0 % and n02, 0.7 %), administrative
problems (0 % and n02, 0.7 %), loss to follow-up (0 % and
n01, 0.3 %), and death (0 % and n03, 1 % [pneumonia, n01;
sepsis, n02]).
The AEs leading to discontinuation (regardless of
relationship to deferasirox) in the <7 mg Fe/g dw cohort
were diarrhea (n02), eyelid edema (n01), generalized
edema (n01), cholelithiasis (n01), and disease progression







bMalignant disease or congenital
anemia
cPatients received DFP
and DFO, but not necessarily
in combination
dOther category is not mutually
exclusive; patients who received
DFO and/or DFP and other
chelation therapies are counted
under both categories
LIC <7 mg Fe/g dw
(n071)
LIC ≥7 mg Fe/g dw
(n0303)
Mean age±SD, years 27.5±17.8 23.1±14.7
Age group, n (%)
2 to <6 years 9 (12.7) 8 (2.6)
6 to <12 years 5 (7.0) 35 (11.6)
12 to 16 years 7 (9.9) 53 (17.5)
≥16 years 50 (70.4) 207 (68.3)
Female/male, n 35:36 154:149
Race, n (%)
Caucasian 48 (67.6) 137 (45.2)
Black 3 (4.2) 7 (2.3)
Oriental 15 (21.1) 148 (48.8)
Other 5 (7.0) 11 (3.6)
Underlying disease, n (%)
Thalassemiaa 58 (81.7) 259 (85.5)
MDS 6 (8.5) 15 (5.0)
SCD 4 (5.6) 15 (5.0)
Rare anemia 2 (2.8) 6 (2.0)
Aplastic anemia 1 (1.4) 5 (1.7)
Other anemiab – 3 (1.0)
History of hepatitis B and/or C, n (%) 29 (40.8) 66 (21.8)
Splenectomy, n (%) 32 (45.1) 125 (41.3)
Previous chelation therapy, n (%)
DFO monotherapy 50 (70.4) 191 (63.0)
DFP monotherapy – 3 (1.0)
DFO and DFPc 10 (14.1) 85 (28.1)
Otherd – 2 (0.7)
None 11 (15.5) 23 (7.6)
Mean number of transfusion sessions±SD
in the year prior to study entry
15.4±9.3 15.8±10.9
Mean volume transfused±SD in the year
prior to study entry, mL/kg
180.1±231.1 158.7±161.5
Mean duration of transfusions±SD, years 19.7±13.6 16.8±8.8
Mean baseline LIC±SD, mg Fe/g dw 4.6±1.7 25.0±10.6
Median baseline serum ferritin (range), ng/mL 1,479 (462–4,365) 4,139 (716–18,126)
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(n01). AEs leading to discontinuation in the ≥7 mg Fe/g dw
cohort were sepsis (n03), vomiting (n02), cardiomyopathy,
abdominal pain, constipation, diarrhea, nausea, adverse
drug reaction, pneumonia, increased blood creatinine,
hemosiderosis, fistula, muscle weakness, dizziness, nephritis,
acute renal failure, renal tubular disorder, angioedema,
swelling face, and urticaria (all n01; note that patients could
have multiple AEs reported as reason for discontinuation).
The most common investigator-assessed drug-related AEs
observed in each LIC cohort are shown in Table 4.
In the <7 mg Fe/g dw cohort, there was one case of
investigator-assessed drug-related severe diarrhea in a patient
withMDS. In the ≥7 mg Fe/g dw cohort, there were four cases
of investigator-assessed drug-related severe rash; three of
these occurred in patients with thalassemia, the fourth in a
patient with MDS. The most frequently reported drug-related
AEs were gastrointestinal (Table 4). These occurred more
frequently in the <7 mg Fe/g dw cohort than the ≥7 mg Fe/g
dw cohort (39.4 versus 20.8 %; P00.001). Rates of discon-
tinuation as a result of drug-related gastrointestinal AEs were
low: Two patients in the LIC <7 mg Fe/g dw cohort discon-
tinued as a result of diarrhea and three patients in the ≥7 mg
Fe/g dw cohort discontinued as a result of constipation,
diarrhea, nausea, and vomiting.
Multivariate analysis was conducted in order to determine
whether any baseline patient characteristics influenced the
observed difference in the occurrence of drug-related gastro-
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Fig. 2 Mean LIC±SD at
baseline and after 12 months
of deferasirox treatment
by baseline LIC category.
*P<0.0001 versus baseline
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This analysis revealed that patients with LIC <7 mg Fe/g dw
have a higher risk of gastrointestinal AEs, which was not
confounded by diagnosis, dosing, ethnicity, or history of
hepatitis B and/or C. This analysis also demonstrated a mild
interactive effect between LIC <7 mg Fe/g dw and
history of hepatitis B and/or C, resulting in a higher
incidence of gastrointestinal AEs in thalassemia patients
with both LIC <7 mg Fe/g dw and a history of hepatitis B
and/or C compared with patients with LIC <7 mg Fe/g
dw and no history of hepatitis B and/or C (46.2 versus
28.1 %, respectively). However, this did not reach statistical
significance.
When determining whether ethnicity influenced the
incidence of gastrointestinal AEs, the analysis showed
that non-Oriental patients had a higher risk of gastrointestinal
AEs, which was not confounded by diagnosis, baseline
LIC category, or history of hepatitis B and/or C. Eighteen
(11.0 %) Oriental patients were reported to have a gas-
trointestinal AE compared with 6 (60.0 %), 55 (30.1 %),
and 12 (75.0 %) patients of Black, Caucasian, and other
ethnicity, respectively.
Serious AEs were noted in 6 patients (8.5 %) in the
<7 mg Fe/g dw cohort and 38 patients (12.5 %) in the
≥7 mg Fe/g dw cohort. None of the serious AEs occurring
in the <7 mg Fe/g dw cohort were considered to be
drug-related by the investigator. In the ≥7 mg Fe/g dw
cohort, three patients (all with β-thalassemia) experienced
serious AEs considered to be drug-related; one patient
experienced renal tubular disorder of moderate intensity
and the other two patients experienced serious AEs of
severe intensity (angioedema and nephritis/acute renal
failure). Three patients (all in the ≥7 mg Fe/g dw cohort)
died during the study; one patient with underlying aplastic
anemia died as a result of pneumonia and two patients
(one with underlying malignant disease and one with
underlying thalassemia) died as a result of sepsis. No
cause of death was considered to be drug-related.
Overall, 21 (29.6 %) patients in the <7 mg Fe/g dw
cohort and 105 (34.7 %) patients in the ≥7 mg Fe/g dw
cohort had two or more consecutive increases in serum
creatinine >33 % above baseline; all patients had low or
normal levels at baseline. The proportion of patients with
two or more consecutive increases in serum creatinine
levels >33 % above baseline and above the upper limit
of normal (ULN) was similar in the <7 mg Fe/g dw
cohort (n05, 7.0 %; thalassemia, n04; MDS, n01) and
Table 2 Patients with LIC <7,
7 to <10, and ≥10 mg Fe/g dw
at baseline and after 12 months
by baseline LIC category
aIf no value was available
at 12 months, the last
available post-baseline value
was considered
Baseline LIC LIC category after 12 monthsa, mg Fe/g dw [n (%)]
<7 7 to <10 ≥10
<7 mg Fe/g dw (n071) 63 (88.7) 4 (5.6) 4 (5.6)
7 to <10 mg Fe/g dw (n025) 15 (60.0) 10 (40.0) –
≥10 mg Fe/g dw (n0278) 31 (11.2) 36 (12.9) 211 (75.9)









































Baseline Week 52Week 24
Baseline LIC ≥7 mg Fe/g dw
303 286 273
Baseline Week 52Week 24
Fig. 3 Median serum
ferritin±25th/75th percentiles
during deferasirox treatment
by LIC at baseline.
*P<0.0001 versus baseline
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≥7 mg Fe/g dw cohort (n016, 5.3 %; thalassemia, n08;
MDS, n05; SCD, n01; malignant disease, n01; rare
anemia, n01). Five of these patients subsequently received
specific dose reductions for a laboratory test abnormality.
When investigator-reported AEs are considered (Table 4),
increased blood creatinine was not reported more frequently
in patients with baseline LIC <7 mg Fe/g dw compared
with ≥7 mg Fe/g dw.
Three patients had two consecutive alanine amino-
transferase (ALT) values >10 times ULN during deferasirox
treatment: one (1.4 %) in the <7 mg Fe/g dw cohort
(thalassemia and hepatitis B/C-positive) and two
Table 3 Absolute changes from baseline by baseline LIC category and average actual deferasirox dose for LIC and serum ferritin
Baseline LIC, mg Fe/g dw
<7 (n071) ≥7 (n0303)


















Mean LIC±SD at baseline,
mg Fe/g dw
3.4±1.2 4.7±1.7 5.0±1.4 – 16.6±6.0 19.3±9.2 27.5±9.8 31.6±9.8
Mean LIC±SD at 12 months,
mg Fe/g dw
2.6±1.3 4.4±2.2 6.1±3.5 – 12.1±9.3 14.8±10.4 20.8±12.0 23.9±12.6
Mean change in LIC±SD,
mg Fe/g dw
−0.4±1.1 −0.2±2.1 0.7±3.3 – −4.6±4.7 −4.2±7.0 −6.9±9.6 −7.3±10.7




878 1,527 1,882 – 2,464 3,151 4,555 6,230
Median serum ferritin
at 12 months, ng/mL
966 1,553 1,593 – 2,799 2,395 3,693 5,141
Median change in serum
ferritin, ng/mL
−28 −62 −16 – 154 −434 −1,003 −1,496
P valuea NS NS NS – NS 0.0121 <0.0001 0.0004
NS not significant, SD standard deviation
a Paired two-sided t test based on mean change from baseline
Table 4 Most common investigator-assessed drug-related AEs (≥5 % in either group overall) by baseline LIC category and severity
AE, n (%) Baseline LIC, mg Fe/g dw
<7 (n071) ≥7 (n0303)
Severity Severity
Mild Mod Severe Total Mild Mod Severe Total
Diarrhea 15 (21.1) 2 (2.8) 1 (1.4) 18 (25.4) 26 (8.6) 5 (1.7) 0 31 (10.2)
Abdominal pain 7 (9.9) 2 (2.8) 0 9 (12.7) 9 (3.0) 3 (1.0) 0 12 (4.0)
Upper abdominal pain 6 (8.5) 1 (1.4) 0 7 (9.9) 12 (4.0) 1 (0.3) 0 13 (4.3)
Constipation 6 (8.5) 1 (1.4) 0 7 (9.9) 9 (3.0) 0 0 9 (3.0)
Nausea 4 (5.6) 2 (2.8) 0 6 (8.5) 11 (3.6) 5 (1.7) 0 16 (5.3)
Abdominal distension 5 (7.0) 0 0 5 (7.0) 7 (2.3) 1 (0.3) 0 8 (2.6)
Rash 4 (5.6) 1 (1.4) 0 5 (7.0) 21 (6.9) 14 (4.6) 4 (1.3) 39 (12.9)
Abnormal LF test 3 (4.2) 1 (1.4) 0 4 (5.6) 2 (0.7) 1 (0.3) 0 3 (1.0)
Increased blood creatinine 0 0 0 0 29 (9.6) 9 (3.0) 0 38 (12.5)
LF liver function, mod moderate
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(0.7 %) in the ≥7 mg Fe/g dw cohort (thalassemia and
hepatitis B/C-positive, n01; thalassemia and hepatitis
B/C-negative, n01). Both hepatitis B/C-positive patients
received dose reductions/interruptions as a result of
laboratory test abnormalities, with ALT levels returning
to within the normal range.
Discussion
With widening therapeutic and investigative/monitoring
options in iron chelation therapy, an emerging theme
includes the benefits and safety of achieving target LIC
<7 mg Fe/g dw. In this 1-year substudy of the EPIC trial,
LIC and serum ferritin levels were successfully maintained
in patients with baseline LIC <7 mg Fe/g dw, while those
with baseline LIC ≥7 mg Fe/g dw achieved significant
reductions, with 60.0 % of patients with baseline LIC 7 to
<10 mg Fe/g dw shifting to LIC <7 mg Fe/g dw after
12 months; it is probable that treatment for longer than 1 year
would be required for many patients with higher baseline
LICs to achieve their therapeutic goal. Such effects on iron
balance appeared to be dose-related, since maintenance of
LIC and serum ferritin levels in patients with baseline LIC
<7 mg Fe/g dw was achieved at a lower mean dose of
20.7 mg/kg/day, whereas in those with baseline LIC
≥7 mg Fe/g dw, significant reductions in LIC and serum
ferritin were achieved at a mean dose of 27.1 mg/kg/day.
This supports the findings from a previous trial, which
suggested that a deferasirox dose of 20 mg/kg/day is a
suitable maintenance dose and doses of 30 mg/kg/day are
required to achieve negative iron balance in regularly trans-
fused β-thalassemia patients [18]. Moreover, subanalyses in
the present study based on average actual deferasirox dose
indicated dose-related reductions in LIC and serum ferritin
levels in the ≥7 mg Fe/g dw cohort. The median time to a
dose increase in this 52-week study was relatively long,
ranging from 18 to 43 weeks. As some patients require
higher doses to achieve their therapeutic goal, it might
reasonably be hypothesized that a greater proportion of
patients would have achieved their therapeutic goal if dose
increases had been carried out more promptly. More rapid
dose escalations are particularly important in patients
requiring a reduction in iron burden, such as those with
LIC ≥7 mg Fe/g dw.
The data presented here from the EPIC study build on
data already shown for a smaller number of patients with
LIC <7 and ≥7 mg Fe/g dw in the ESCALATOR trial [16].
In ESCALATOR, patients with β-thalassemia who were
previously unsuccessfully chelated with DFO and/or
deferiprone (DFP) also achieved their therapeutic goal
of LIC reduction when treated with deferasirox despite
high iron burden at baseline (90 % had LIC ≥7 mg Fe/g dw)
[16]. In our subset of patients, the proportion with LIC ≥7 mg
Fe/g dw was slightly lower (81 %) and that with LIC <7 mg
Fe/g dw was higher (19 %) than in the ESCALATOR study,
allowing a more detailed comparison between the low and
high iron burden groups. In addition, the present study
expands these findings to patients with other transfusion-
dependent anemias, including MDS, SCD, and other rare
anemias that were also included in this MRI substudy.
Although the safety profile of deferasirox has been
investigated in many trials, there are limited data evaluating
deferasirox doses of 20 mg/kg/day in patients with a
lower iron burden. The ESCALATOR trial found no
clear trends in the type or frequency of drug-related
AEs between the LIC <7 and ≥7 mg Fe/g dw cohorts
[16]. In addition, a small study (n019) by Grosse et al.
showed no safety concerns at a median deferasirox dose
of 19 mg/kg/day in patients with LIC <6 mg Fe/g dw
[15]. Safety evaluation of larger patient numbers, as seen
here, was required to corroborate these findings. In this study,
deferasirox treatment had a clinically manageable safety
profile in patients with baseline LIC <7 and ≥7 mg Fe/g dw,
thus confirming the tolerability profile of deferasirox
20 mg/kg/day in patients with lower iron burdens. The
discontinuation rate as a result of AEs was low in both
groups and only four patients overall withdrew consent.
Interestingly, fewer patients in the <7 mg Fe/g dw cohort
experienced drug-related rash and increased blood creatinine
noted as investigator-assessed AEs. Laboratory data con-
firming two or more consecutive increases in serum
creatinine >33 % above baseline over 1 year were consistent
with previous studies [18–20]. Importantly, this study did not
show an increased risk of renal toxicity at LIC <7 mg Fe/g dw
compared with those patients treated at higher LIC values.
Patients in the <7 mg Fe/g dw cohort experienced more
gastrointestinal AEs than those in the ≥7 mg Fe/g dw cohort.
The multivariate analysis showed that the higher risk of
gastrointestinal AEs in patients within the LIC <7 mg Fe/g dw
cohort occurred irrespective of diagnosis, dosing, ethnicity,
and history of hepatitis B and/or C. This might suggest
that these generally mild-to-moderate gastrointestinal
effects are exacerbated by iron deprivation in the gut as
a result of chelation therapy, but this requires confirma-
tion. There was also an indication that patients with low
baseline LIC who have a history of hepatitis B and/or C
are at a higher risk of gastrointestinal AEs compared
with those with low baseline LIC without a history of
hepatitis B and/or C, although this interaction was not
statistically significant and, therefore, requires confirmation
through additional studies.
Non-Oriental patients had a higher risk of gastrointestinal
AEs irrespective of diagnosis, baseline LIC category, and
history of hepatitis B and/or C. Differences in safety profile
between ethnic backgrounds in the EPIC study have also been
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recently highlighted elsewhere, whereby patients from the
Asia-Pacific region (89.0 % Oriental background) reported a
higher incidence of skin rash compared with those in the rest
of the world [21]. It is, therefore, possible that pharmacoge-
netics may be important when managing patients treated with
deferasirox; however, further investigations are warranted.
In conclusion, this study confirms that deferasirox doses
of 20 mg/kg/day over 1 year enables patients to maintain
LIC <7 mg Fe/g dw and that deferasirox doses of approxi-
mately 30 mg/kg/day are required to achieve a significant
reduction in LIC in patients with baseline LIC ≥7 mg Fe/g
dw. There was a clinically manageable safety profile in both
LIC cohorts. The increased incidence of mild-to-moderate
gastrointestinal AEs in patients with LIC <7 mg Fe/g dw
requires confirmation in other patient groups to provide fur-
ther insight into possible mechanisms for this observation.
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